4°congresso sezione triveneto sio udine 4 ottobre 2008 la terapia farmacologica dell obesit à...
TRANSCRIPT
![Page 1: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/1.jpg)
4°Congresso SEZIONE TRIVENETO SIO
Udine 4 Ottobre 2008
La terapia Farmacologica dell’obesità
Vincenzo Di Francesco
Clinica Geriatrica Università di VeronaServizio di Nutrizione Clinica
![Page 2: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/2.jpg)
Obiettivi del trattamentoObiettivi del trattamento
Obesità
Tempo
Peso corporeo Storia naturale
Stabilizzazione
Opzione 5-10%
Normalizzazione
![Page 3: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/3.jpg)
Atherogenic dyslipidemia Triglycerides
HDL-cholesterol Cholesterol/HDL- ratio
apo B Small, dense LDL and HDLPostprandial hyperlipidemia
Insulin resistanceInsulin resistanceHyperinsulinemiaHyperglycemiaType 2 diabetes
Thrombotic state PAI-1
Fibrinogen
Inflammatory state CRP
Cytokines risk of acute
coronary syndromeMetabolic risk factorsAbdominal obesity
Inflammation
Lipid coreThin fibrous cap
CORONARY ATHEROSCLEROSISUNSTABLE PLAQUE
Intra-abdominal obesity, metabolic risk factors and CHD
Adapted from Despres, 2004
![Page 4: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/4.jpg)
![Page 5: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/5.jpg)
2006
![Page 6: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/6.jpg)
1999
![Page 7: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/7.jpg)
2003
![Page 8: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/8.jpg)
2003
![Page 9: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/9.jpg)
Orlistat
MGMG Bile
acidsBile acids
MicelleMicelle
MG
FA
Lipase +
Orlistat
Lipase +
Orlistat
30%30%
Intestinal lumenTG
Intestinal lumenTG
LymphaticsLymphatics
Mucosal cellMucosal cell
![Page 10: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/10.jpg)
XENDOS 2005
![Page 11: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/11.jpg)
XENDOS 2005
![Page 12: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/12.jpg)
Oil spotting…
![Page 13: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/13.jpg)
• Centrally acting weight loss agent• Serotonin and norepinephrine
reuptake inhibitor
Sibutramine Mode of Action
Reduces Reduces decline in decline in metabolicmetabolicrate post rate post
weight loss weight loss
Reduces Reduces decline in decline in metabolicmetabolicrate post rate post
weight loss weight loss
Enhances Enhances satiety/ feeling satiety/ feeling
of fullnessof fullness
Enhances Enhances satiety/ feeling satiety/ feeling
of fullnessof fullness
Caloric Intake Caloric Intake Caloric Expenditure
Caloric Expenditure
![Page 14: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/14.jpg)
Mean percentage weight change over 12 months achieved by non-diabetic (DM) and DM patients according to achievement of 4kg weight
loss target at month 3 (3M).
Finer, N. et al, 2006
![Page 15: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/15.jpg)
Finer, N. Eur Heart J Suppl 2005 7:L32-38L
Weight loss and maintenance in the STORM trial. (Adapted from James et al.)
![Page 16: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/16.jpg)
![Page 17: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/17.jpg)
Finer, N. Eur Heart J Suppl 2005 7.
Changes in systolic blood pressure by weight loss category(Adapted from Sharma, 2001)
![Page 18: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/18.jpg)
Bensaid M et al, 2003; Pagotto U et al, 2005;
Osei-Hyiaman D et al, 2005;Di Marzo V et al, 2005; Liu YL et al, 2005
Adipose tissue
MuscleLiverGI tract
Increased food intakeIncreased fat storage
Insulin resistanceHDL-CTGGlucose uptakeAdiponectin
Hypothalamus: hunger
Nucleus accumbens: motivation to eat ^
^
^^
Brain Peripheral tissues
Central and peripheral targets of ECS and effects of
overactivity
Rimonabant
![Page 19: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/19.jpg)
RIO combi, 2008
![Page 20: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/20.jpg)
Copyright restrictions may apply.
Nissen, S. E. et al. JAMA 2008;299:1547-1560.
Effects of Rimonabant on Body Weight, Waist Circumference, and Levels of High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Fasting Insulin, and Glycated Hemoglobin
(HbA1c)
![Page 21: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/21.jpg)
![Page 22: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/22.jpg)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis Diana Rucker, Raj Padwal, Stephanie K Li, Cintia Curioni, David C W Lau
Women 60 - 75% Age 45-50Mean weight 100 kg
Orlistat16 trial10.631
Sibutramina10 trial2.623
Rimonabant4 trial6.635
33%
48%
45%
![Page 23: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/23.jpg)
Copyright ©2007 BMJ Publishing Group Ltd.
Rucker, D. et al. BMJ 2007;335:1194-1199
Placebo subtracted weight reduction (kg) with orlistat
![Page 24: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/24.jpg)
-2,5
-2
-1,5
-1
-0,5
0waist BP T-Chol HDL TGL A1-Hb
0
5
10
15
20
25
30
GI side effects Incontinence Drop-out
Orlistat
![Page 25: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/25.jpg)
Copyright ©2007 BMJ Publishing Group Ltd.
Rucker, D. et al. BMJ 2007;335:1194-1199
Placebo subtracted weight reduction (kg) with sibutramine
![Page 26: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/26.jpg)
-5
-4
-3
-2
-1
0
1
2
3
4
5
waist BP HDL TGL HR
0
5
10
15
20
25
Side effects Drop-out
Sibutramine
![Page 27: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/27.jpg)
Copyright ©2007 BMJ Publishing Group Ltd.
Rucker, D. et al. BMJ 2007;335:1194-1199
Placebo subtracted weight reduction (kg) with rimonabant
![Page 28: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/28.jpg)
-4,5
-4
-3,5
-3
-2,5
-2
-1,5
-1
-0,5
0
0,5
waist BP T-Chol HDL TGL A1-Hb
0
1
2
3
4
5
6
7
serious SE Psychiatric SE Drop-out
Rimonabant
![Page 29: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/29.jpg)
Aspetti controversi relativi all’uso dei farmaci nella terapia
dell’obesità
• Tempistica e durata del trattamento
• Selezione dei pazienti
• Ricerca dei “responders”
• Parametri di successo terapeutico
• Costo/beneficio
![Page 30: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/30.jpg)
R Padwal, 2007
Long-term persistence
![Page 31: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/31.jpg)
“Irrespective of which drug is initially selected, treatment should be discontinued if clinically significant weight loss (ie, at least 5-10% of initial bodyweight or improvement in major obesity-related comorbidity) does not occur within the first 3-6 months”
R Padwal, 2007
![Page 32: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/32.jpg)
![Page 33: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/33.jpg)
Orlistat (120 mg x 3) € 3,50/dì
Sibutramina (10 mg x 1) € 2,75/dì
Rimonabant (20 mg x 1) € 4,10/dì
3-4 caffè!20-33% della mia pensione..
![Page 34: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/34.jpg)
Drugs on the HorizonDrugs on the HorizonOther CB-1 AntagonistsOther CB-1 Antagonists
NPY Receptor antagonistNPY Receptor antagonist
Serotonin 2C Receptor AgonistsSerotonin 2C Receptor Agonists
PYY 3-36PYY 3-36
OxyntomodulinOxyntomodulin
Pancreatic Lipase Inhibitor (Cetilistat)Pancreatic Lipase Inhibitor (Cetilistat)
Growth Hormone Fragment (lipolitic)Growth Hormone Fragment (lipolitic)
![Page 35: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/35.jpg)
Weight loss is the primary endpoint. Demonstration of a clinically significant degree of weight loss of at least 10% of baseline weight, which is also at least 5% greater than that associated with placebo, is considered to be a valid primary efficacy criterion in clinical trials evaluating new anti-obesity drugs.
![Page 36: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/36.jpg)
2006
![Page 37: 4°Congresso SEZIONE TRIVENETO SIO Udine 4 Ottobre 2008 La terapia Farmacologica dell obesit à Vincenzo Di Francesco Clinica Geriatrica Universit à di Verona](https://reader036.vdocuments.pub/reader036/viewer/2022062417/551607cc550346a2308b4f29/html5/thumbnails/37.jpg)
Grazie per l’attenzione!